期刊名称：CIRCULATION-CARDIOVASCULAR INTERVENTIONS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Circulation: Cardiovascular Interventions will include articles related to research in and the practice of the broad field of interventional cardiology (coronary, structural, adult congenital and peripheral vascular). Observational studies, clinical trials, and advances in applied (translational) research will be considered.
Manuscripts are examined by the editorial staff and usually evaluated by expert reviewers assigned by the editors. Both clinical and basic articles will also be subject to statistical review, when appropriate. Provisional or final acceptance is based on originality, scientific content, and topical balance of the journal. Decisions are communicated by email, generally within six weeks. The editors will not discuss a decision about a manuscript over the phone. All rebuttals must be submitted in writing to the editorial office.
Instructions to Authors
Circulation: Cardiovascular Interventions publishes several types of manuscripts under the umbrella of full-length articles. A brief description of each type follows:
Original Research Articles
Circulation: Cardiovascular Interventions considers all types of original research articles, including experiments conducted in human subjects, laboratory animals, in vitro and in silico.
Review Series
Please note that the editors invite most review articles. However, unsolicited material will be considered for publication.
Advances in Interventional Cardiology: Articles will include cutting edge contemporary reviews of important topics in cardiovascular interventions. Emphasis will be placed on areas where recent advances in the understanding of the mechanisms of disease, diagnosis and treatment including drug therapy, devices and new techniques have altered clinical practice.
Contemporary Reviews in Interventional Cardiology: Reviews will bring insights from basic investigations into cardiac physiology and pathophysiology into context for the clinician.
Controversies in Interventional Cardiology: Controversial topics in interventional cardiology will be presented in this series. Opposite viewpoints will be presented in tandem, with rebuttal responses by both authors included. Alternatively, a single review of a controversial area with a balanced presentation of the opposing views will be presented.
Special Sections
Book Reviews: Reviews of selected books on cardiovascular interventions, including books that present innovative concepts, books that describe state-of-the-art diagnostic and therapeutic methods or important advances, and textbooks will be reviewed in this section. Unsolicited book reviews will be considered for publication online. In addition, authors or publishers may submit books, as well as a list of suggested reviewers, to the editorial office at the address noted above.
Correspondence: Letters to the Editor, which pertain directly to an article published in the journal within the preceding 8 weeks, will be considered for publication online. A letter must not exceed 500 words in length and must be limited to three authors and five references. They should not have tables or figures. Authors of the original article cited in the letter will be invited to reply. Letters to the editor should be submitted via the online manuscript submission process as described below.
Expert Opinions: The purpose of this series is to provide an expert opinion concerning an important clinical trial that has the potential to change practice or concerning the management of a clinical issue where clinical trials are lacking or conflicting. The paper should include sufficient background to justify your opinion. Expert Opinions should be between 3000 and 5000 words.
Images and Case Reports in Interventional Cardiology: Clinical images (including motion studies) that illustrate either important "classic" or novel findings. The images and case report should provide useful and significant information to guide clinical care, provide insight into basic mechanisms responsible for cardiovascular disease or the understanding or outcomes of interventions, , or elucidate a new therapy. The written portion of the submission should include a title page, descriptive text of no more than two pages with up to 4 references (if appropriate) and a figure legend. The images should be of high quality and clearly demonstrate the abnormality or intervention and the significance of the findings. Movie clips are encouraged and may be submitted in any of the standard formats (e.g. avi, mov, etc) and codecs.
General Preparation Instructions:
Maximum Word Length: 6000 words
Word Count includes title page, abstract, text, references, tables, and figure legends
Maximum Number of References: 50
Maximum Number of Figures and Figure Legends: 8
Manuscript should be typed double-spaced, including title page, abstract, text, references, figure legends, and tables. Text should only appear on one side of the page. Acceptable formats are Word or WordPerfect.
Leave a 1-inch margin on all sides. Do not use justified margins.
Cite references, figures, and tables in numeric order. For review, acceptable figure formats are GIF, TIFF, EPS, JPEG, and single slides of Power Point.
Formats NOT supported are as follows: Object Linking and Embedding (OLE), Bitmap (.bmp), PICT (.pict), Excel (.xls), Photoshop (.psd), Canvas (.cnv), CorelDRAW (.cdr), and locked or encrypted PDFs. For publication, see acceptable figure requirements under "Accepted Manuscripts " below.
Use SI units of measure. A more conventionally used measurement may follow in parentheses. Make all conversions before manuscript submission.
Please provide sex-specific and/or racial/ethnic-specific data when appropriate, in describing the outcomes of epidemiologic analyses or clinical trials; or specifically state that no sex-based or racial/ethnic-based differences were present.
Consult the American Medical Association Manual of Style, 10th ed, New York, Oxford University Press, 2007, for style.
Manuscripts must conform to the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" http://www.icmje.org/.
Assemble the manuscript in this order: Title Page, Abstract, Text, Acknowledgments, Funding Sources, Disclosures, References, Figure Legends, Tables, and Figures.
Title Page
The title page (page 1, do not number) should contain these elements:
Full title
First author's surname and short title (not to exceed 50 characters, including spaces)
Authors' names, academic degrees, and affiliations
Name and complete address for correspondence (include street name and address as well as post office box, and address for reprints if different from correspondence)
Fax number, telephone number and email address
The total word count of the manuscript, including the title page, abstract, text, references, tables and figures legends
The Journal Subject Codes pertaining to the article. Please refer to the subject code list.
Abstract and Key Words
Do not cite references in the abstract
Limit use of acronyms and abbreviations. Define at first use acronym or abbreviation in parenthesis.
Be concise (250 words maximum)
Use the following headings:
Background - rationale for study
Methods and Results - brief presentation of methods and presentation of significant results; please include sample size
Conclusions - succinct statement of data interpretation
When applicable, include a fourth heading: "Clinical Trial Registration". Please list the URL, as well as the Unique Identifier, for the publicly accessible website on which the trial is registered.
Insert three to five Key Words after abstract. Please refer to the key word list.
Text
Typical main headings include Methods, Results, and Discussion
Number pages
Abbreviations must be defined at first mention
Methods
Please note that the print version of the Methods and Results should be able to stand alone and should provide sufficient information for the reader to understand the basic methods of the study and to review the fundamental findings in a mechanistic way.
Experimental animals: State the species, strain, number used, and pertinent descriptive characteristics. When describing surgical procedures, identify the preanesthetic and anesthetic agents used and the amounts, concentrations, routes, and frequency of administration of each. Paralytic agents are not considered acceptable substitutes for anesthetics. For other invasive procedures on animals, report the analgesic or tranquilizing drug used. If none were used, provide justification for exclusion.
Human studies: Indicate that the study was approved by an institutional review committee and that the subjects gave informed consent.
Drugs and Devices: In the Methods, the complete name and location of the manufacturer must be supplied for all reagents, equipment, and devices used. In all other instances, the generic rather than trademark names of all drugs and devices.
Independent Data Access and Analysis: The Editors consider it preferable for investigators to have direct access to the primary data in a clinical trial (raw and derived datasets) when reporting results of the trial. Alternatively, an independent party with an academic affiliation who has access to the primary data may serve as the analyst for the investigators. It is recognized that for logistical reasons these options may not be possible in all instances. At a minimum, the authors should have the ability to query any aspect of the data either directly or through an independent analysis. However, the Editors reserve the right to ask for additional information from the corresponding author regarding measures that were taken to minimize bias and verify the integrity of the primary data and any analyses performed.
Guidelines for Clinical Trials
In accordance with the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (Circulation. 2005;111:1337) and (http://content.nejm.org/cgi/content/full/NEJMe078110), all clinical trials in Circulation: Cardiovascular Interventions must be registered in a public trials registry at or before the onset of participant enrollment. This requirement applies to all clinical trials that began enrollment after July 1, 2005.
Research is considered to be a clinical trial if it involves prospective assignment of human subjects to an intervention or comparison group to study the relation between a health-related intervention and a health outcome. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. As previously, purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration. We will start to implement the expanded definition of clinically directive trials for all trials that began enrollment on or after July 1, 2008. Those who are uncertain whether their trial meets the expanded ICMJE definition should err on the side of registration if they wish to seek publication.
The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, and managed by a not-for-profit organization. The registry must include the following information: a unique identifying number, a statement of the intervention(s), study hypothesis, definition of primary and secondary outcome measurements, eligibility criteria, target number of subjects, funding source, contact information for the principal investigator, and key dates (registration date, start date, and completion date). The registry sponsored by the United States National Library of Medicine (http://www.clinicaltrials.gov) meets these requirements and is recommended by the editors.
Other registries are acceptable if they meet these requirements. In addition to www.clinicaltrials.gov, the following registries are recommended by the ICMJE:
http://isrctn.org
http://www.umin.ac.jp/ctr/index/htm/
http://www.anzctr.org.au/Default.aspx
http://www.trialregister.nl/trialreg/index.asp
In accordance with the ICMJE's recommendation, we will also accept registration of clinical trials in any of the primary registers that participate in the World Health Organization's International Clinical Trial Registry Platform. Primary registers are WHO selected registers managed by not-for-profit entities that will accept registrations for any interventional trials, delete duplicate entries from their own register, and provide data directly to the WHO. Please note that registration in any WHO partner registers is insufficient.
The authors will be requested to provide the exact URL and unique identification number for the trial registration at the time of submission. Since this information will be published, we ask that you include a fourth heading in your abstract: "Clinical Trial Registration Information". Please list the URL, as well as the unique identifier, for the publicly accessible website on which the trial is registered in this section.
Clinical trial reports should also comply with the Consolidated Standards of Reporting Trials (CONSORT) and include a flow diagram presenting the enrollment, intervention allocation, follow-up, and data analysis with number of subjects for each (http://www.consort-statement.org/?o=1011). Please also refer specifically to the CONSORT Checklist of items to include when reporting a randomized clinical trial.
Results posted in the same clinical trials registry in which the primary registration resides will not be considered prior publication if they are presented in the form of a brief abstract (500 words or less) or a table.
Guidelines for Meta-Analyses
See "Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting," JAMA. 2000; 283: 2008-2012.
Guidelines for Studies on Diagnostic Tests
See "The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration," Ann Intern Med. 2003; 138: 40-44.
Guidelines for Human Phenotype-Genotype Association or Linkage Studies
Reporting issues:
Report process for selecting genes and SNPs.
Report Hardy-Weinberg statistics or p-values and method of calculating same.
Refer to existing public domain websites for the Human Gene Ontology name and the rs number for SNPs: http://www.ncbi.nlm.nih.gov/projects/SNP/ and http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Snp
Describe genotyping methods. If numerous primers have been used, please include them in an online supplement.
False positive and false negative concerns. Given well-described problems with both false positive and false negative associations, phenotype-genotype association studies should meet some or all of the criteria below:
Phenotype is clearly defined, is heritable, and if a quantitative phenotype is reported, reproducibility data are provided.
The sample size is adequate to detect a SNP or haplotype with a modest effect. For genotype-trait associations, provide an estimate of the effect size that could be detected with power 0.80 or higher with the allele frequency and sample size reported.
Since multiple statistical testing methods are frequently used in genotyping-phenotyping studies, please include specifics of the primary model(s) tested. Nonessential secondary models may be published as electronic data supplements. Clinically relevant confounders should be included in multivariable models or residuals.
Review criteria for human linkage studies. Manuscripts should include the following:
Identifying plausible candidate genes under the linkage peak.
Follow-up fine mapping to narrow the region of linkage, and/or genotyping some of the candidate genes under the linkage peak.
Replication data from another sample.
Guidelines for Genomic and Proteomic Studies
Preparation of Data Submitted: Data should follow the MIAME checklist (for more information see http://www.mged.org/Workgroups/MIAME/miame_checklist.html).
Accessibility of Data: Authors of papers that include genomic, proteomic, or other high-throughput data are required to make their data easily accessible for the reviewers and the editors during the review process.
You may submit your data to the NCBI gene expression and hybridization array data repository (GEO, http://www.ncbi.nlm.nih.gov/geo/) and provide the GEO accession number; or,
You may provide a link to a secure or publicly accessible website which hosts the data. Prior to publication, the data must be submitted and an accession number obtained. Access to the information in the database must be available at the time of publication. GEO has a web-based submission route, suitable for a small number of samples, or a batch submission tool (called SOFT). GEO is accessible from http://www.ncbi.nlm.nih.gov/geo/. The submission FAQ is available at http://www.ncbi.nlm.nih.gov/projects/geo/info/faq.html.
Guidelines for Proteins and Nucleic Acid Sequences
Newly reported nucleotide or protein sequences must be deposited in GenBank or EMBL databases, and an accession number must be obtained. Access to the information in the database must be available at the time of publication. Authors are responsible for arranging release of data at the time of publication. The authors must also provide a statement in the manuscript that this sequence has been scanned against the database and all sequences with significant relatedness to the new sequence identified (and their accession numbers included in the text of the manuscript).
GenBank
GenBank Submissions
National Center for Biotechnology Information
8600 Rockville Pike, Building 38A
Room 8N-805
Bethesda, MD 20894
Tel: (301) 496-2475
On the web at: http://www.ncbi.nlm.nih.gov/Genbank/index.html
EMBL Nucleotide Sequence Submissions
European Bioinformatics Institute
Hinxton Hall
Hinxton, Cambridge CB10 1SD, UK
Tel.: 44-1223-494401; Fax: 44-1223-494472
e-mail: support@ebi.ac.uk
On the web at: http://www.ebi.ac.uk
DNA Data Bank of Japan
Center for Information Biology
National Institute of Genetics
Mishima, Shizuoka, 411, Japan
Tel.: 81-559-81-6853; Fax: 81-559-81-6849
On the web at: http://www.ddbj.nig.ac.jp
Submission to any data bank is sufficient to ensure entry in all.
Acknowledgments
Authors should obtain written permission from all individuals who are listed in the "Acknowledgments" section of the manuscript, because readers may infer their endorsement of data and conclusions. The corresponding author must sign the Acknowledgment Section of the Copyright Transfer Agreement, certifying that (1) all persons who have made substantial contributions in the manuscript (eg, data collection, analysis, or writing or editing assistance), but who do not fulfill authorship criteria, are named with their specific contributions in the Acknowledgments section of the manuscript; (2) all persons named in the acknowledgments section have provided the corresponding author with written permission to be named in the manuscript; and (3) if an Acknowledgments section is not included, no other persons have made substantial contributions to this manuscript.
Funding Sources
All sources of support for the research should be listed under this heading.
All grant funding agency abbreviations should be completely spelled out, with the exception of the NIH.
Disclosures
All potential conflicts of interest must be stated within the text of the manuscript, under this heading. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors, or being publicly associated with the company or its products. Other areas of real or perceived conflict of interest could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations. Please state "None" if no conflicts exist.
References
Accuracy of reference data is the responsibility of the author
Verify all references against original sources
List all authors for each reference; do not use "et al. "
Example reference: 1. Smith HJ, Allen S, Yu W, Fard S. This is the title. Circulation. 2004; 104:276-308.
Please note that if you use reference software tools (e.g. EndNote or Reference Manager), they do not always match our style and you may need to manually correct your references..
Cite references in numeric order according to first mention in the text. In the text, ensure accuracy of spelling and details of publication, i.e., the text citation should match the reference information.
Personal communications, unpublished observations, and submitted manuscripts are not legitimate references. They must be cited in the text only (not in the reference list) as follows: author name, degree(s) held, unpublished data, year.
Abstracts may be cited only if they are the sole source and must be identified in the reference as "Abstract."
References must be from a full length publication in a peer reviewed journal.
"In press" citations must have been accepted for publication and the name of the journal or book publisher must be included.
Figures
Figure parts should be clearly labeled. Letters and locants must be uniform in size and style within each figure, and when possible, between figures. (The font size must be 10 point or higher.)
Avoid headings on the figure. Heading information should appear in the figure legend.
Line art should not contain hair lines, which are hard to reproduce
Supply a scale bar with photomicrographs
Provide double-spaced copy for figure legends on a separate page
Symbols and abbreviations must be defined in the figure or its legend
Limit white space between the panel and panel label
Figures should be sized as close as possible to their final print size. Please note that very few figures qualify for a 2-column format.
Tables
Begin each table on a separate page, double-spaced. Please remember that tables prepared with Excel are not accepted unless embedded within your text document.
The table number should be Arabic, followed by a period and brief title
Use same size type as in text
Supply a brief heading for each column
Indicate footnotes in this order: *, †, ‡, §, | |, #, * *
Do not use vertical lines between columns. Use horizontal lines above and below the column headings and at the bottom of the table only. Use extra space to delineate sections within the table.
Abbreviations used in the table must be defined in a footnote to the table.
Online Data Supplements
Online Data Supplements are encouraged as an enhancement to the print Methods section. This optional section provides an opportunity to present supporting materials to the manuscript. Please note that all supplements undergo peer review and must be submitted with the original submission of the manuscript.
Online Data Supplements can consist of the following:
Expanded Methods and Results
Additional Figures
Additional Tables
Video Files
If citations are made in an Online Data Supplement, the supplement must contain its own Reference Section, with references numbered sequentially beginning with the number 1. Please try to keep the individual file size to 10 MB or less to facilitate easier downloading for readers.
Online Supplemental Data: A combined PDF of your supplemental data must be provided. The first page of this PDF should include the heading, "SUPPLEMENTAL MATERIAL." Please note that this single PDF would include all of the supplemental material related to your manuscript, except for the Video or Movie files. The supplemental material to be included in this PDF is as follows: Supplemental Methods, Supplemental Tables, Supplemental Figures and Figure Legends, and Supplemental References. Lastly, the legends for the Video files should also be included in this PDF. Please upload this PDF to your author area.
Supplemental Materials Required for Review
A copy of all submitted manuscripts mentioned in the article must be submitted as part of the review process
A copy of all manuscripts, either in preparation or submitted, that potentially overlap with your Circulation: Cardiovascular Interventions submission. Please note that failure to include such material is a violation of the journal's Ethical Policy, below.
A copy of all in press articles cited in the Reference section must be supplied for review by the editors and the reviewers
Ethical Policy
Manuscripts are considered on the understanding that they contain original material, that the manuscript and material within the manuscript have not been published and are not being considered for publication elsewhere in whole or in part in any language, including publicly accessible web sites or e-print servers, except as an abstract. The authors also certify that any and all other work in preparation, submitted, in press, or published that is potentially overlapping either in the actual data presented or in the conceptual approach is enclosed along with the original submission. Any material within the manuscript that has appeared elsewhere must be cross-referenced and permission to use or adapt the material must be received, in writing from the copyright holder.
Abstracts and Webcasts
If some or all of the work in the manuscript has been published or submitted in abstract form, and/or overlapping data exists, the following rules apply:
The published or submitted abstract must accompany the submitted manuscript.
The abstract cannot itself have been referenced in MEDLINE or PubMed.
The potentially overlapping work and a separate explanation of the nature of any possible overlap with the submitted manuscript must accompany the submitted manuscript.
These restrictions generally do not apply to presentations or press reports published in connection with scientific meetings, or to poster presentations at scientific meetings that are videotaped, provided that the material has not been widely circulated, copyrighted or sold. Posting an audio recording, video recording, or short summary of a presentation made at a professional meeting on the Internet would be considered as a meeting presentation by the American Heart Association and would not compromise consideration of a submission. Direct release of information through press releases or media briefings may preclude publication.
Embargo Policy
All content information of an accepted paper is strictly confidential and cannot appear in the media (in print or electronic form) before its embargo date and time. Authors/researchers, their respective public relations representatives and funding sponsors may not distribute or promote their work to the media prior to embargo.
In the event that the American Heart Association/American Stroke Association selects the manuscript for promotion in a news release, news conference, video news release or podcast, AHA/ASA staff will contact the author/researcher to inform him/her of the pending news materials and to notify him/her that he/she may give reporters pre-embargo interviews based upon the media requests generated by the AHA/ASA news materials. Authors/researchers must ensure that the reporter understands and will adhere to the embargo time.
If an embargo break is the result of any action by an author/researcher, he/she risks withdrawal of publication of his/her manuscript. Violations of the embargo policy may also jeopardize future acceptance of manuscripts to be published in AHA/ASA scientific journals.
Generally, embargoes on journal articles lift the day and the time the article is published, either on-line or in print (whichever comes first) by the American Heart Association/American Stroke Association.
Questions about media embargoes should be directed to Bridgette McNeill, Senior Communications Manager, Science Media Operations, AHA National Center, 7272 Greenville Avenue, Dallas, TX 75231-4596; Tel: 214-706-1135; Email: bridgette.mcneill@heart.org.
Although the Editorial Office will endeavor to notify authors of the anticipated publication date/time, neither the Editorial Office nor the AHA/ASA will be responsible for any consequences of early online posting with regard to the intellectual property rights. To safeguard their intellectual property, authors should ensure that appropriate reports of invention and patent applications have been filed before the manuscript is accepted.
How to Submit a Manuscript:
General Online Submission Information
All manuscripts must be submitted electronically. Before proceeding to the online submission site, please prepare your manuscript according to the instructions listed above under the heading, "How to Prepare a Manuscript." When your manuscript is ready for submission, please follow the instructions below.
Go to the following website: http://submit-circ.ahajournals.org. Also, please note that online submission help is available by calling the Editorial Office or by emailing circhelp@circulationjournal.org
Create an accoung or log in to the manuscript tracking system.
To create an account:
Please note that if you are an author, reviewer, or editor for any journal that uses Bench>Press, you automatically have an account with Circulation: Cardiovascular Interventions, and you should use the same login information for submission to a journal that you use for the other journal(s). For a complete list of Bench>Press journals, please visit the current Bench>Press journals list.
When you are ready to create an account, please select the Create A New Account link on our submission home page. Here you will be prompted to enter your email to check if you already have a preexisting account with us or with another Bench>Press journal. If you have a preexisting, but unregistered account, you will be instructed on how to complete the registration process. If the test shows that you have a fully registered account, but you cannot remember your registration information, you can click the "Send My Registration" button. An email will be sent to you with your information, including how to obtain your password if you forgot it. If the email test reports that you have no preexisting account, you may follow the website's instructions to create a new account.
To log into existing account:
User name = Email Address. Please note that only one email address can be registered at any given time and serve as your login. If you use several email addresses and are uncertain about which email address represents your login for this site, please contact the Editorial Office for assistance.
Password: If you have forgotten your password, you can obtain a new one by going to the I Have Forgotten My Password area. Here you will be prompted to enter your email address. The next page will ask you your security question. If you incorrectly enter the security question, a button will appear that you can click to email the answer to you.
Step-by-Step Online Submission Instructions
Enter the Author Area. Select the Submit a New Manuscript link.
Complete the following form fields as a part of the Manuscript Information:
Select Number of Authors
Article Type
Title
Short/Running Title (50 characters or less, including spaces)
Abstract (250 words or less)
Cover Letter
Suggested Reviewers and Excluded Reviewers, including the first name, last name, institution, email, telephone and fax numbers, as well as address.
Clinical Trial Registration Information: You will be required to note whether or not your clinical trial is registered, and you will be asked to provide the URL for where the trial is registered as well as the registration number.
Public Access Policy Funding Disclosure: You will be asked to disclose the funding source for the research on which your article is based. If your research was funded by the National Institutes of Health, the Wellcome Trust, or the Howard Hughes Medical Institute, it must be noted.
Select Subject Codes.
Select Key Words.
Enter Author Information. Required for each author are email address, first name, last name and institution.
Upload your manuscript file(s). You have three options in this regard:
Create a single Word document with the tables and figures embedded. (Recommended for best file quality and compression.)
Create a single PDF document that includes your tables and figures.
Upload each manuscript file separately.
If uploading manuscript TEXT files separately, only Word, WordPerfect and PDF are acceptable formats.
If uploading manuscript TABLE files separately, only Word, WordPerfect and PDF are acceptable formats. However, you may embed a table created with excel into your text document and upload your tables as part of your text.
If uploading manuscript FIGURE files separately, only GIF, TIFF, EPS, JPG and single slides of PowerPoint are acceptable formats.
PDF approval: After you upload your manuscript file(s), your manuscript will undergo a conversion process. You must return to the submission area and enter the "Ready for You to Proof" section to approve your manuscript submission and the PDF that will be used for review.
Please Note that no hard copies of either the text or the figures are required for review. However, as the author, it is your responsibility to ensure that the PDF used is of the highest quality.
Prior to publication, the Copyright Transfer Agreement form must be completed by each author and faxed to the editorial office. To ensure proper handling, it is suggested that the corresponding author collect the completed forms from each author and fax them, simultaneously, to the Editorial Office. Please note the American Heart Association's new Authorship Responsibility and Copyright Transfer Agreement form, a link to which can be found at the top of this page.
Signed letters from all persons acknowledged by name. These documents do not need to be turned into the editorial office, unless specifically requested. The corresponding author should retain these for his/her records.
Revised Manuscripts:
All revisions must be received within 90 days of the original decision date. If your revision is not received within that specified time limit, the manuscript will be considered de novo.
Please remember that your manuscript text, including title page, abstract, references, figure legends, and tables, should not exceed 6,000 words. Manuscripts exceeding this limit will be returned to authors for further revision, prior to review. Word count is calculated by the Editorial Office using the Microsoft Word tool.
Please label each page of your revision using your manuscript number followed by /R1, /R2, /R3, etc.
In your written response to the reviewers' comments, give the exact page number(s), paragraphs(s) and line number(s) where each revision was made.
Enter Conflict of Interest Disclosures. You will need to describe conflicts regarding this manuscript for all authors. Please refer to the Online Conflict Reference Form prior to submission.
Original manuscript files should be submitted electronically to the Editorial Office, so as not to delay publication if and when the paper is accepted.
Compliance With NIH and Other Research Funding Agency Accessibility Requirements
Several research funding agencies now require or request authors to submit the post-print (the article after peer review and acceptance but not the final published article) to a repository that is accessible online by all without charge. Within medical research, 3 funding agencies in particular have announced such policies:
The US National Institutes of Health (NIH) requires authors to deposit post-prints of articles, which have received NIH funding, in its repository PubMed Central (PMC). This deposit should be done within the 12 months after publication of the final article in the journal.
The Howard Hughes Medical Institute (HHMI) requires, as a condition of research grants, deposit in PMC, but within 6 months after publication of the final article.
The Wellcome Trust requires, as a condition of research grants, deposit in UK PMC within 6 months after publication of the final article.
As a service to authors, the Publisher (Wolters Kluwer Health/Lippincott Williams & Wilkins) of the AHA journals will identify to PMC articles that require depositing. The Copyright Transfer Agreement provides the primary mechanism for identifying such articles. The AHA also requests that, during the submission process in Bench>Press, funding is indicated in the first page of the submission process.
WKH/LWW will transmit the post-print of an article, which is based on research funded in whole or in part by 1 or more of these 3 agencies, to PMC.
On NIH request, it remains the legal responsibility of the author(s) to confirm with the NIH the provenance of their manuscript for purposes of deposit.
Author(s) will not deposit their articles themselves.
Author(s) will not alter the post-print already transmitted to NIH.
Author(s) will not authorize the display of the post-print prior to 12 months after publication of the final article, in the case of NIH, or 6 months after publication of the final article, in the case of HHMI and the Wellcome Trust.
For more information about authors' rights and responsibilities, please visit the AHA Authorship Responsibility and Copyright Transfer Agreement.
For more information on PMC, please visit http://nihms.nih.gov.
A Permissions and Rights Question and Answer is also available; please visit http://www.ahajournals.org/rights.
Accepted Manuscripts:
The following are required for publication:
Original source files for the manuscript text, tables and figures.
For detailed information about submitting print publication-quality digital art, please visit http://circ.ahajournals.org/misc/ifora.pdf.
Only TIFF (tagged image file format), EPS (encapsulated postscript) and PPT (Microsoft PowerPoint) files are acceptable for publication.
Color files must be saved as CMYK (Cyan-Magenta-Yellow-Black) not RGB Red-Green-Blue).
Line art must be saved at resolution of at least 1200 dpi; photographs, CT scans, radiographs, etc, should be saved at a resolution of at least 300 dpi. Images saved at 72 dpi are not acceptable for printed publications.
PowerPoint files can be acceptable, although PowerPoint is not a recommended application for image preparation. Color figures submitted as PowerPoint may experience a shift in hue. PowerPoint files must contain only supported fonts (Arial, Helvetica, Times Roman, and Symbol). If other fonts are used in the PowerPoint file or in EPS files embedded in a PowerPoint document, there is a significant chance of formatting errors or character substitutions. Images must be embedded in PowerPoint files, rather than "linked".
Each panel of the figure should be saved in a separate file.
Prior to publication, the Copyright Transfer Agreement form must be completed by each author and faxed to the editorial office. To ensure proper handling, it is suggested that the corresponding author collect the completed forms from each author and fax them, simultaneously, to the Editorial Office. Please note the American Heart Association's new Authorship Responsibility and Copyright Transfer Agreement form, a link to which can be found at the top of this page.
Written permissions from all persons acknowledged by name should be collected and retained by the corresponding author.
Online Supplemental Data: A combined PDF of your supplemental data must be provided. The first page of this PDF should include the heading, "SUPPLEMENTAL MATERIAL." Please note that this single PDF would include all of the supplemental material related to your manuscript, except for the Video or Movie files. The supplemental material to be included in this PDF is as follows: Supplemental Methods, Supplemental Tables, Supplemental Figures and Figure Legends, and Supplemental References. Lastly, the legends for the Video files should also be included in this PDF. Please upload this PDF to your author area.
Timely publication of a manuscript will depend upon all of the above.
Accepted Images in Cardiovascular Medicine:
Submit the image as TIFF, at one of the following resolutions:
Color: 300 dpi
Grayscale: 600 dpi
Line art: 1200 dpi
Text-based graphics should be provided as 300 dpi, closecropped TIFFs, sized to match print.
To maximize the size of the figures on the PDF/reprint, figures should be submitted at the width of 2 columns (about 6.75 inches, 40 picas wide).
Lastly, as a reminder, all Patient Identification information, e.g., the patient's name, must be removed from all figure and movie files. If a patient can be recognized from the image, we must receive a waiver signed by the patient, stating that he/she agrees to have his/her identity revealed.
Cost to Authors
Fee per printed black and white page: $70;
Fee per printed color page: $465;
Supplemental fee for exceeding the word limit:
Authors of papers exceeding our 6,000 word limit will be charged for the overage. Minimum fee for papers exceeding this maximum will be $425. In addition, authors will be charged an additional $425 for each additional 1,000 words over 6,000. The usual $70 page charge will also apply. Word count will be calculated by the editorial office, using the Microsoft Word tool. Title page, abstract, references, tables and figures legends are included in the total word count.
Reprint expenses: Price lists are sent with author's proofs.
Excessive author alterations to typeset page: $50 per page.
Correction (erratum): $100 per page if error results from an author's oversight.
Permissions
Requests for permission to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Interventions can be obtained via Rightslink (a service of the Copyright Clearance Center), not the Editorial Office. All permission requests are now processed via the Rightslink online system. Steps for obtaining permission include:
On the Circulation: Cardiovascular Interventions home page, either search for the article using the Search feature or locate a copy of the article in the online archives for which you are requesting permission.
Next, select the Full Text or PDF version of the article.
Then, locate the "Request Permissions" link in the menu on the right side of the Web page (under "Services"). A new Web browser will open, which is Rightslink.
Follow the step-by-step instructions in Rightslink for requesting permission by:
selecting the way the content will be used.
creating an account, if one does not exist already.
accepting the terms and conditions for reuse.
determining method of payment.
Further information can be found in the Permissions and Rights Instructions.
Note: For AHA Scientific Statements and Guidelines, permission to reprint, modify, alter, enhance, copy, or distribute this content must be obtained from the American Heart Association. Instructions are located at http://www.americanheart.org/presenter.jhtml?identifier=4431. A link to the "Permission Request Form" appears on the right side of the Web page, in the "Related Items" box.
Conflict of Interest Policy for Editors
Original manuscripts authored or coauthored by the Editor (in Chief), the Deputy Editor, Senior Associate Editor, or any of the Associate Editors are handled by a Consulting Editor, who makes all the decisions about the manuscript (including choice of referees and ultimate acceptance or rejection). The entire process is handled confidentially. All manuscripts submitted from the Editor's home institution are also handled entirely by a Consulting Editor. The Editor (in Chief) may additionally, from time to time, refer a manuscript to a Consulting Editor to avoid a real or reasonably perceived conflict of interest.
Disclaimer
Statements, opinions, and results of studies published in Circulation: Cardiovascular Interventions are those of the authors and do not reflect the policy or position of the American Heart Association, and the American Heart Association provides no warranty as to their accuracy or reliability.
Editorial Board
For Authors, Reviewers, and General Peer Review Inquiries:
Circulation
560 Harrison Avenue, Suite 502
Boston, MA 02118
Phone: 617-542-5100
Fax: 617-542-6539 E-mail: circ@circulationjournal.org
| 
刊名字顺( Alphabetical List of Journals):
返回页首 